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EDITORIAL
Introduction
In the fall of 1998, Nancy Santilli, Director of
Epilepsy, Eisai Inc., visited the National Epilepsy
Center in Shizuoka, Japan, where she gave a pre-
sentation on comprehensive care of patients with
epilepsy. After the meeting was over, Ms. San-
tilli told us of Eisai’s desire to hold a roundtable
meeting to discuss the antiepilepsy drug (AED),
zonisamide, and her hope that Japanese epilepsy
experts could participate and share their experi-
ences with their US and European colleagues.
The International Zonisamide Roundtable meet-
ing, which was held in Tokyo, Japan, 8—9 May 1999,
brought together 16 epilepsy experts from Japan,
the United States, and Europe to discuss their ex-
periences with zonisamide. Japanese participants
shared the knowledge they have accumulated in
more than a decade of zonisamide use, and US
and European participants shared results from the
latest zonisamide clinical trials in their respective
countries.
In Japan, zonisamide is a well-established
antiepilepsy drug. In the United States, it has only
recently been approved; and in European countries,
it has not yet been launched. On the other hand,
in Western countries, many new AEDs are avail-
able. But in Japan, these same new AEDs are still
undergoing clinical trials. Because the availability
and experience with AEDs, including zonisamide,
differ considerably in Japan compared to Western
countries, this meeting focused on exchanging in-
formation regarding the clinical use of zonisamide.
Epilepsy is a condition that has a signiﬁcant im-
pact on the lives of those it affects. Our hope is
that the information exchanged during this Inter-
national Roundtable will expand worldwide knowl-
edge of antiepilepsy drugs and further the efforts
of neurologists as they endeavor to treat their pa-
tients.
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